Open AccessOnce-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study
Author(s) -
Satish Modi,
Robert Lehmann,
Thomas R. Walters,
Raymond Fong,
William C. Christie,
Lawrence Roel,
David A. Nethery,
Dana Sager,
Alexis Tsorbatzoglou,
Bo Philipson,
Carlo Enrico Traverso,
Harvey Reiser
Publication year - 2014
Publication title -
journal of cataract and refractive surgery/journal of cataract and refractive surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.678
H-Index - 142
eISSN - 1873-4502
pISSN - 0886-3350
DOI - 10.1016/j.jcrs.2013.07.042
Subject(s) - medicine , cataract surgery , randomized controlled trial , surgery , clinical endpoint , ophthalmology , confidence interval , anesthesia
To evaluate once-daily nepafenac 0.3% to prevent and treat ocular pain and inflammation after cataract surgery.